■在大流行开始时,建议将含有抗SARS-CoV-2抗体的COVID-19恢复期血浆(CCP)作为治疗来源。在过去的3年里,许多试验证明CCP治疗的有效性有限.这导致我们假设中共可能包含其他元素,以及所需的中和抗体,这可能会阻止它产生治疗效果,其中细胞因子,趋化因子,生长因子,凝血因子,和自身抗体。
■总共,在190名献血者的血浆中分析了39种细胞因子,进一步的研究集中在CCP中23种不同的细胞因子(sCD40L,eotaxin,FGF-2,FLT-3L,ractalkine,GRO-α,IFNα2,IL-1β,IL-1RA,IL-5、IL-6、IL-8、IL-12、IL-13、IL-15、IL-17E、IP-10,MCP-1,MIP-1b,PDGF-AA,TGFα,TNFα,和TRAIL)。在CCP中检测到抗SARS-CoV-2抗体和中和抗体。
■我们发现在首次出现COVID-19症状后最多180天内服用的CCP与对照组之间没有显着差异。我们还比较了低中和抗体(<160)组和高中和抗体(≥160)组之间的细胞因子水平,发现两组之间没有差异。我们的研究还显示与抗SARS-CoV-2IgGAb的水平或中和抗体的水平没有相关性。根据COVID-19症状开始后的一段时间,细胞因子水平也没有显著变化。
■没有发现可能导致预防CCP产生治疗作用的元素。
UNASSIGNED: At the beginning of the pandemic, COVID-19 convalescent plasma (CCP) containing anti-SARS-CoV-2 antibodies was suggested as a source of therapy. In the last 3 years, many trials have demonstrated the limited usefulness of CCP therapy. This led us to the hypothesis that CCP could contain other elements, along with the desired neutralizing antibodies, which could potentially prevent it from having a therapeutic effect, among them cytokines, chemokines, growth factors, clotting factors, and autoantibodies.
UNASSIGNED: In total, 39 cytokines were analyzed in the plasma of 190 blood donors, and further research focused on the levels of 23 different cytokines in CCP (sCD40L, eotaxin, FGF-2, FLT-3L, ractalkine, GRO-α, IFNα2, IL-1β, IL-1RA, IL-5, IL-6, IL-8, IL-12, IL-13, IL-15, IL-17E, IP-10, MCP-1, MIP-1b, PDGF-AA, TGFα, TNFα, and TRAIL). Anti-SARS-CoV-2 antibodies and neutralizing antibodies were detected in CCP.
UNASSIGNED: We found no significant differences between CCP taken within a maximum of 180 days from the onset of the first COVID-19 symptoms and the controls. We also made a comparison of the cytokine levels between the low neutralizing antibodies (<160) group and the high neutralizing antibodies (≥160) group and found there were no differences between the groups. Our research also showed no correlation either to levels of anti-SARS-CoV-2 IgG Ab or to the levels of neutralizing antibodies. There were also no significant changes in cytokine levels based on the period after the start of COVID-19 symptoms.
UNASSIGNED: No elements which could potentially be responsible for preventing CCP from having a therapeutic effect were found.